Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Zdenka Leko-Mohr"'
Publikováno v:
American Journal of Kidney Diseases. 40:458-463
Background: Angiotensin-converting enzyme (ACE) inhibitors effectively reduce proteinuria; however, the optimal antiproteinuric dose is still unknown. We conducted this study to determine whether an increase in ACE-inhibitor dose above the maximal an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::110efc1c2339b3caa9de8b1ef70c39a5
https://doi.org/10.1053/ajkd.2002.34883
https://doi.org/10.1053/ajkd.2002.34883
Autor:
Markus Exner, Martin Haas, Wilfred Druml, Georg A. Böhmig, Kurt Derfler, Heinz Regele, Walter H. Hörl, Zdenka Leko-Mohr
Publikováno v:
Nephrology Dialysis Transplantation. 17:1503-1508
Background. Re-transplanted kidney allograft recipients with high levels of panel reactive antibodies (PRA) are at increased risk of early immunologic graft loss. In these patients, prophylactic peri-operative antibody depletion by immunoadsorption (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aba5901948c1bbfdbd4372cda5460001
https://doi.org/10.1093/ndt/17.8.1503
https://doi.org/10.1093/ndt/17.8.1503
Autor:
Günter Delling, Christoph Schwarz, Josef Kletzmayr, Christoph Domenig, Rainer Oberbauer, Klaus Klaushofer, Martin Haas, Thomas Zsontsich, Zdenka Leko-Mohr, Paul Roschger
Publikováno v:
American Journal of Kidney Diseases. 39:580-586
Osteoprotegerin (OPG) has a profound inhibitory effect on osteoclast differentiation and bone resorption. Because high-turnover renal osteodystrophy (ROD) is characterized by increased osteoclast activity, serum OPG concentrations might be used to di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf5d609ef5c718a28851aea4103e2293
https://doi.org/10.1053/ajkd.2002.31409
https://doi.org/10.1053/ajkd.2002.31409
Autor:
Stefan Grampp, Christa Mitterbauer, Paul Roschger, Günter Delling, Klaus Klaushofer, Christoph Schwarz, Zdenka Leko-Mohr, Josef Kletzmayr, Rainer Oberbauer, Rudolf Steininger, Martin Haas
Publikováno v:
Kidney International. (3):1130-1136
Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Background Bisphosphonates can prevent bone mineral density loss after renal transplantation, but their effect on trabecular mineralization and bone morphology, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87d5ea739a0a2a9bc4e40348ce6d2517